List of Excipients in Branded Drug COMBIGAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	COMBIGAN	brimonidine tartrate, timolol maleate	0023-9211	BENZALKONIUM CHLORIDE
Allergan Inc	COMBIGAN	brimonidine tartrate, timolol maleate	0023-9211	HYDROCHLORIC ACID
Allergan Inc	COMBIGAN	brimonidine tartrate, timolol maleate	0023-9211	SODIUM HYDROXIDE

Combigan Excipient Strategy, Formulation Opportunities, and Patent Exposure

Last updated: October 26, 2026

COMBIGAN combines brimonidine tartrate 0.2% and timolol maleate 0.5% in a preserved ophthalmic solution. Its excipient system is conventional and commercially vulnerable: benzalkonium chloride, phosphate buffers, sodium chloride, water, and pH adjusters support a low-cost multidose product, but leave room for differentiated preservative-free, low-irritation, and advanced-delivery products. The strongest opportunities are formulation improvements rather than protection of the existing excipient combination.

What is the COMBIGAN formulation and which excipients does it contain?

COMBIGAN is an ophthalmic solution containing two active ingredients:

Component	Concentration or function
Brimonidine tartrate	0.2%
Timolol maleate	0.68%, equivalent to 0.5% timolol
Benzalkonium chloride	0.005% preservative
Sodium chloride	Tonicity adjustment
Sodium phosphate dibasic heptahydrate	Buffer
Sodium phosphate monobasic monohydrate	Buffer
Hydrochloric acid and sodium hydroxide	pH adjustment
Purified water	Vehicle

The product is indicated to reduce elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or additional therapy. The labeled administration is one drop in the affected eye or eyes twice daily, approximately 12 hours apart. The product is supplied in multidose ophthalmic containers. [1]

The formulation has no listed viscosity-enhancing polymer, surfactant, cyclodextrin, lipid, or mucoadhesive excipient. That simplifies manufacturing and supports a low-cost generic strategy, but it also creates opportunities for competitors to improve residence time, comfort, preservative exposure, and packaging.

What excipient functions are commercially important in COMBIGAN?

Preservative system

Benzalkonium chloride, or BAK, is the principal differentiation point. At 0.005%, BAK provides antimicrobial preservation for the multidose bottle. Repeated exposure can contribute to ocular-surface irritation, tear-film disruption, and concerns in patients with chronic glaucoma therapy or concomitant ocular-surface disease.

A preservative-free version could target:

• Patients with dry-eye disease
• Patients receiving multiple topical glaucoma products
• Postoperative or chronic-use populations
• Patients with ocular-surface intolerance
• Prescribers seeking to reduce cumulative BAK exposure

A BAK-free multidose product would require validated container-closure technology or an antimicrobial dispensing system. A unit-dose product would remove the need for a conventional preservative but would increase packaging, filling, logistics, and waste costs.

Buffer system

COMBIGAN uses a phosphate buffer system. Buffer concentration and pH affect:

• Brimonidine and timolol chemical stability
• Ocular comfort
• Solubility and precipitation risk
• Compatibility with the container
• Sterilization and storage performance

A lower-buffer or alternative-buffer formulation could be positioned around improved tolerability. Potential systems include citrate, borate, or low-capacity mixed buffers, subject to compatibility and regulatory support. A buffer change would require a full assessment of pH drift, degradation products, osmolality, preservative effectiveness, and active-ingredient assay.

Tonicity control

Sodium chloride supports ocular isotonicity. Tonicity is commercially relevant because deviations can affect comfort and patient acceptance, especially in formulations with altered active concentrations or increased polymer content.

A reformulated product should control osmolality without creating precipitation or changing drop comfort. Sodium chloride reduction may be possible if another excipient contributes to tonicity, but this would require optimization rather than simple substitution.

Vehicle and rheology

The current product uses purified water without a listed viscosity modifier. A modest viscosity increase could improve precorneal residence time and reduce drainage through the nasolacrimal duct. Candidate excipients could include:

• Hydroxypropyl methylcellulose
• Hydroxypropyl cellulose
• Polyvinyl alcohol
• Carbomers
• Hyaluronic acid or sodium hyaluronate
• Poloxamers

The commercial trade-off is material. Higher viscosity may improve exposure but can produce blurred vision, drop-stringing, bottle-flow problems, or variable delivered volume. A polymer-based product also faces increased preservative compatibility and sterilization requirements.

What formulation patents and excipient claims could protect a COMBIGAN follow-on?

A follow-on product would obtain stronger protection from a coordinated formulation and delivery estate than from a simple excipient substitution.

Protection area	Potential claim focus	Commercial value
Preservative-free formulation	Brimonidine and timolol in a sterile unit-dose or preservative-free multidose system	High for chronic-use and ocular-surface patients
Alternative preservative	Polyquaternium-1, oxidative preservatives, or other ophthalmic systems	Moderate, subject to tolerability evidence
Low-irritation buffer	Defined pH and buffer capacity with reduced ocular-surface burden	Moderate
Viscosity-enhanced formulation	Polymer concentration, viscosity range, and residence-time profile	Moderate to high
Container-closure system	One-way valve, antimicrobial bottle, or metered dispenser	High if device claims are enforceable
Stability profile	Defined impurity limits and shelf life for the dual-active solution	Moderate
Dosing system	Metered-volume or adherence-supporting dispenser	Moderate to high
Method of use	Reduced dosing frequency or treatment of a defined patient subgroup	High if clinically differentiated
Manufacturing process	Order of addition, filtration, sterilization, or pH adjustment sequence	Moderate, but harder to detect in the market

The most defensible claims would combine composition and performance limitations. Examples include a preservative-free brimonidine/timolol solution with a specified pH, osmolality, viscosity, impurity profile, and container system. A broad claim covering only “brimonidine plus timolol in an ophthalmic solution” is exposed to prior-art and obviousness challenges.

Device claims can be valuable because a competitor may reproduce the active formulation while avoiding the specific dispensing architecture. A combined formulation-device portfolio also creates more settlement leverage than a single composition patent.

What is the Orange Book status and patent position for COMBIGAN?

COMBIGAN is an FDA-approved small-molecule combination product, not a biologic. Biosimilar litigation does not apply. The relevant competitive pathway is an abbreviated new drug application, or ANDA, for a therapeutically equivalent brimonidine tartrate/timolol maleate ophthalmic solution.

The principal patent risk has historically centered on patents covering the brimonidine-timolol combination and related ophthalmic compositions. The foundational estate no longer provides the type of long-term exclusivity associated with a newly launched product. Current commercial barriers are more likely to involve regulatory requirements, product quality, manufacturing scale, physician adoption, and device differentiation than an unexpired core composition patent.

Legal and regulatory issue	Assessment
Core active combination	Mature small-molecule technology
Biosimilar exposure	None
ANDA pathway	Primary route for therapeutically equivalent products
Orange Book relevance	Relevant for listed patents and Paragraph IV certifications
Formulation patents	Potentially important for new preservative-free or device-based products
Method-of-use patents	Possible, but narrow claims require strong clinical differentiation
Device patents	Important for multidose preservative-free delivery
Trade secrets	Relevant to process controls, sterilization, filling, and stability

The FDA Orange Book should be used to confirm the active listing, patent numbers, expiration dates, and any pediatric-exclusivity adjustments at the time of a filing or transaction. FDA approval of generic brimonidine/timolol products demonstrates that the product category has an established ANDA pathway. [2,3]

When did COMBIGAN lose exclusivity and what generic entry risks exist?

The product’s commercial exclusivity has matured. Generic competition can attack the product through:

1. A standard ANDA with Paragraph III certification to wait for patent expiry.
2. A Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.
3. A formulation design that avoids listed patents while retaining the same active ingredients.
4. A differentiated 505(b)(2) product with a new excipient system, device, dosing regimen, or preservative-free presentation.

The principal risks to the branded product are price compression and formulary substitution. Ophthalmic generics also face practical barriers, including sterile manufacturing, container-closure validation, extractables and leachables, drop-size consistency, microbial control, and stability.

A generic does not need to reproduce every commercial attribute of the brand. It generally must satisfy the applicable sameness and therapeutic-equivalence requirements for the approved reference product. Excipient differences can be acceptable when they do not affect safety, efficacy, or product performance under the applicable FDA standards.

Which companies are challenging or competing with COMBIGAN?

The competitive field includes three groups:

Generic manufacturers

Generic ophthalmic companies can compete on:

• Wholesale acquisition cost
• Retail substitution
• Pharmacy supply reliability
• Bottle size and packaging
• Contract manufacturing capacity
• Formulary access

Companies active in generic ophthalmic products have included large U.S. and international manufacturers such as Teva, Apotex, Sandoz, Lupin, and Micro Labs, depending on product availability and market period. Product-specific marketing status must be verified through FDA listings and current commercial databases.

Branded fixed-combination products

COMBIGAN competes indirectly with other fixed or adjunctive glaucoma therapies, including:

• Dorzolamide/timolol combinations
• Brinzolamide/brimonidine combinations
• Prostaglandin analogs
• Rho kinase inhibitors
• Separate brimonidine and timolol bottles

The combination’s commercial value is based on reducing bottle burden while combining an alpha-2 adrenergic agonist with a beta blocker. It is less differentiated where patients require prostaglandin-first therapy, preservative-free products, or therapies with lower systemic beta-blocker exposure.

Reformulated premium products

A preservative-free or low-preservative product could compete without relying on the original brand’s excipient profile. A successful product would need more than BAK removal. It would require a credible benefit in tolerability, adherence, dosing convenience, or ocular exposure.

What are the strongest excipient-based commercial opportunities?

1. Preservative-free multidose COMBIGAN alternative

This is the most attractive opportunity. A preservative-free multidose bottle could preserve convenience while addressing chronic BAK exposure. The key technical requirement is microbial safety after repeated opening and dosing.

Commercial advantages include:

• Premium pricing over standard generic solution
• Differentiation from preserved generics
• Potential adoption by glaucoma specialists
• Positioning in ocular-surface disease
• Reduced need for separate preservative-free adjunctive therapy

The principal risk is device cost and regulatory complexity.

2. Unit-dose preservative-free product

Unit-dose packaging offers a clearer preservative-free proposition. It is technically simpler from a multidose microbial-control perspective but has higher packaging and distribution costs.

The business case is strongest for:

• Surgical centers
• Hospital formularies
• Severe ocular-surface disease
• Short-term postoperative use
• Patients unable to tolerate preserved products

The main limitations are patient handling, waste, portability, and higher per-dose cost.

3. Low-viscosity residence-time formulation

A moderate viscosity increase could improve retention without creating substantial visual blur. This opportunity depends on demonstrating a clinically meaningful outcome, such as lower dosing frequency or reduced systemic drainage.

A product that remains dosed twice daily but has no measured benefit may not justify a premium.

4. Metered-dose dispensing

A dispenser that delivers a consistent smaller drop could reduce product waste and systemic absorption through the nasolacrimal pathway. The device could support claims around dose precision, ease of use, and adherence.

This strategy is attractive because the device can create differentiation even when the chemical formulation remains close to the reference product.

5. Combination products with improved ocular-surface compatibility

A product using a low-irritation buffer, alternative preservative, or preservative-free system could target long-term users with ocular-surface symptoms. Clinical evidence would be necessary to support superiority claims.

How does COMBIGAN compare with alternative glaucoma combinations?

Product category	Main advantage	Main limitation	Excipient opportunity
COMBIGAN	Brimonidine plus timolol in one bottle	BAK exposure and twice-daily dosing	Preservative-free and device reformulation
Dorzolamide/timolol	Established fixed combination	Burning, bitter taste, carbonic anhydrase inhibitor tolerability	Improved pH and comfort
Brinzolamide/brimonidine	No topical beta blocker	Suspension handling and dosing burden	Suspension stability and drop uniformity
Separate agents	Flexible titration	More bottles and lower adherence	Co-packaging or dual-chamber systems
Prostaglandin analogs	Often once-daily use	Iris pigmentation, hypertrichosis, ocular effects	Preservative-free delivery
Novel branded agents	Potentially differentiated mechanisms	Higher cost and limited experience	Advanced delivery and low-dose systems

COMBIGAN’s most direct weakness is not active-ingredient efficacy. It is the preserved multidose format and the burden of chronic topical administration.

What manufacturing and intellectual-property barriers remain?

Sterile ophthalmic manufacturing is the main operational barrier. A commercial product must control:

• Bioburden and sterility assurance
• Active-ingredient assay and content uniformity
• pH and osmolality
• Preservative concentration
• Particulate matter
• Container-closure integrity
• Extractables and leachables
• Drop size and bottle performance
• Stability under long-term and accelerated conditions

The manufacturing process can also generate protectable know-how. Important process variables include the order of excipient addition, dissolution conditions, pH adjustment sequence, filtration method, sterilization approach, and filling environment.

Trade-secret protection may be more durable than narrow process patents where process parameters cannot be detected from the finished product. A patent strategy should therefore combine composition claims, device claims, manufacturing claims, and clinical-use claims.

What licensing and partnering opportunities exist for COMBIGAN-related products?

Potential deal structures include:

• Licensing a preservative-free container system to an ophthalmic manufacturer
• Acquiring a 505(b)(2) formulation with a validated ocular-surface benefit
• Partnering with a contract development and manufacturing organization for sterile filling
• Licensing a metered-dose dispenser with ophthalmic compatibility
• Co-developing a branded generic with a regional ophthalmology company
• Out-licensing a low-cost ANDA platform in emerging markets

The most valuable asset is likely to be a complete product package: formulation, device, stability data, manufacturing process, and clinical tolerability evidence. A standalone excipient patent is less attractive if a competitor can reproduce the commercial benefit through a different excipient or container system.

Key Takeaways

• COMBIGAN contains brimonidine tartrate, timolol maleate, BAK, phosphate buffers, sodium chloride, pH adjusters, and purified water.
• The existing formulation is technically conventional and exposed to generic competition.
• BAK reduction or elimination is the leading excipient-based commercial opportunity.
• Preservative-free multidose delivery offers greater commercial potential than a simple buffer substitution.
• Unit-dose packaging provides a clear clinical proposition but carries higher manufacturing and distribution costs.
• A viscosity-enhanced product requires evidence of better retention, comfort, adherence, or dosing performance.
• Device patents and container-closure technology may provide stronger protection than broad excipient claims.
• COMBIGAN is a small-molecule product with no biosimilar pathway.
• Generic competition is governed primarily by the ANDA and Orange Book framework.
• The most defensible follow-on estate would combine composition, device, manufacturing, stability, and method-of-use claims.

FAQs

Can a generic COMBIGAN product use different excipients?

Yes. An ANDA product may use different inactive ingredients when the differences meet FDA requirements and do not alter safety, efficacy, or therapeutic equivalence. Excipient changes are assessed in the context of the finished ophthalmic product.

Is benzalkonium chloride necessary in COMBIGAN?

BAK is necessary for preservation of the conventional multidose presentation, but not necessarily for every delivery format. A unit-dose or validated preservative-free multidose system could eliminate conventional BAK.

Is COMBIGAN eligible for biosimilar competition?

No. COMBIGAN contains small-molecule active ingredients and is regulated through the drug approval framework. Competition occurs through generic or potentially 505(b)(2) pathways, not biosimilar applications.

Can a preservative-free COMBIGAN formulation obtain new patent protection?

Yes. Patentable subject matter could include a specific preservative-free composition, container system, viscosity range, stability profile, manufacturing process, or method of treating a defined patient population. Patentability depends on novelty, non-obviousness, written description, and claim scope.

What is the best commercial positioning for a COMBIGAN reformulation?

The strongest positioning is a preservative-free, low-irritation, easy-to-administer product with evidence of improved ocular-surface tolerability or dosing performance. A reformulation without a measurable patient or payer benefit would face substantial generic price pressure.

References

1. Allergan, Inc. (2023). COMBIGAN (brimonidine tartrate and timolol maleate) ophthalmic solution prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products. FDA.

4. U.S. Food and Drug Administration. (2019). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. FDA.

5. U.S. Food and Drug Administration. (2023). Guidance for industry: Sterile drug products produced by aseptic processing, current good manufacturing practice. FDA.